

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

21547/0283

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/980006

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/SE00/01026

23 May 2000

31 May 1999

TITLE OF INVENTION

LAYER ARRANGED ON IMPLANT FOR BONE OR TISSUE STRUCTURE, SUCH AN IMPLANT,
AND A METHOD FOR APPLICATION OF THE LAYER

APPLICANT(S) FOR DO/EO/US

HALL, Jan, LAUSMAA, Jukka

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. § 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the Annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter
17. ☒ Other items or information:

International Search Report (ISR); International Preliminary Examination Report (IPER)

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 097/980006		INTERNATIONAL APPLICATION NO. PCT/SE00/01026		ATTORNEY'S DOCKET NUMBER 21547/0283	
<input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO.....\$890.00 International preliminary examination fee paid to USPTO (37 CFR 1.482)\$710.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$740.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$100.00				CALCULATIONS	PTO USE ONLY
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$1,040.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
Claims	Number Filed	Number	Rate		
Total Claims	20 - 20 =	0	X \$18.00	\$	
Independent Claims	3 - 3 =	0	X \$84.00	\$	
Multiple dependent claim(s) (if applicable)			+ \$280.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$1,040.00	
Reduction by 1/2 for filing by small entity, if applicable.				\$	
SUBTOTAL =				\$1,040.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
TOTAL NATIONAL FEE =				\$1,040.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$1,040.00	
				Amount to be:	
				refunded \$	
				charged \$	
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 22-0185 in the amount of \$1,040.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 22-0185 . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status SEND ALL CORRESPONDENCE TO: Connolly Bove Lodge & Hutz LLP 1990 M Street, N.W., Suite 800 Washington, DC 20036-3425					
				SIGNATURE	
				Burton A. Amernick	
				NAME	
				24,852	
				REGISTRATION NUMBER	

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER <div style="text-align: center;">21547/0283</div>
		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <div style="text-align: center; font-size: 1.2em;">097980006</div>
INTERNATIONAL APPLICATION NO. PCT/SE00/01026	INTERNATIONAL FILING DATE 23 May 2000	PRIORITY DATE CLAIMED 31 May 1999
TITLE OF INVENTION LAYER ARRANGED ON IMPLANT FOR BONE OR TISSUE STRUCTURE, SUCH AN IMPLANT, AND A METHOD FOR APPLICATION OF THE LAYER		
APPLICANT(S) FOR DO/EO/US HALL, Jan , LAUSMAA, Jukka		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(h) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the Annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11. to 16. below concern other document(s) or information included:		
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input checked="" type="checkbox"/> A change of power of attorney and/or address letter 16. <input checked="" type="checkbox"/> Other items or information: 		
International Search Report (ISR); International Preliminary Examination Report (IPER)		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

09/980006
JC13 Rec'd PCT/PTO 30 NOV 2001

In re Application of: :
: :
Jan Hall et al. : :
: :
Serial No.: To be assigned : Art Unit: To be assigned
: :
Filed: Herewith : Examiner: To be assigned
: :
For: LAYER ARRANGED ON IMPLANT : Atty Docket: 21547/0283
FOR BONE OR TISSUE STRUCTURE, :
SUCH AN IMPLANT, AND A METHOD :
FOR APPLICATION OF THE LAYER :

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-captioned case as follows.

IN THE CLAIMS

Please amend the claims as follows:

3. (Amended) Implant layer according to Patent Claim 1, characterized in that the channel network (6) has channel branches (10) which extend in directions which are different than the depth direction of the layer or the radial direction of the implant.

4. (Amended) Implant layer according to Patent Claim 1, characterized in that it is established on an undulating or uneven surface (3') present on the

implant from the start and having a high roughness value, for example $0.4 - 5 \mu\text{m}$, for the purpose of increasing the layer volume.

5. (Amended) Implant layer according to Patent Claim 1, characterized in that it has a thickness (T) which gives a substantial corrosion resistance for the implant as a whole.

6. (Amended) Implant layer according to Patent Claim 1, characterized in that the channel network (6) is arranged with a mouth arrangement (3', 4') towards the bone or tissue structure (5), permitting increased bone growth penetration into the channel at the said mouths (compared to conventional oxide layers).

7. (Amended) Implant layer according to Patent Claim 1, characterized in that the layer has an average thickness in the range of $0.5 - 20 \mu\text{m}$, preferably in the range of $2 - 20 \mu\text{m}$.

8. (Amended) Implant layer according to Patent Claim 1, characterized in that the oxide layer has a surface roughness, at its outer surface, in the range of $0.4 - 5 \mu\text{m}$.

9. (Amended) Implant layer according to Patent Claim 1, characterized in that the oxide layer has a high degree of porosity, with a number of $1 \times 10^7 - 1 \times 10^{10}$ pores/cm³.

10. (Amended) Implant layer according to Patent Claim 1, characterized in that each surface has pores or channel mouth areas with diameters or surface area sizes in the range of $0.1 - 10 \mu\text{m}$, and/or in that the total channel network or pore volume lies in a range of 5×10^{-3} and 10^{-5} cm³.

11. (Amended) Implant layer according to Patent Claim 1, characterized in that the layer consists of or comprises a titanium oxide layer.

12. (Amended) Implant layer according to Patent Claim 1, characterized in that the implant consists of a screw implant for application in the jaw bone.

13. (Amended) Implant layer according to Patent Claim 1, characterized in that the layer forms a depot for applied bone-growth-initiating or bone-growth-stimulating agent or substance (17).

14. (Amended) Implant layer according to Patent Claim 1, characterized in that the agent or the substance migrates from the depot to the bone or tissue structure (5) by means of concentration diffusion.

18. (Amended) Method according to Patent Claim 16, characterized in that the position of the implant in the electrolyte is changed together with the composition of the electrolyte (26) and/or the voltage (28) in order to create different oxide thicknesses (T, T') and/or areas of different porosity or pore or channel characteristics.

Please add the following new claims:

19. (New) Implant layer according to Patent Claim 2, characterized in that the channel network (6) has channel branches (10) which extend in directions which are different than the depth direction of the layer or the radial direction of the implant.


20. (New) Implant layer according to Patent Claim 2, characterized in that it is established on an undulating or uneven surface (3') present on the

implant from the start and having a high roughness value, for example 0.4 - 5 μm , for the purpose of increasing the layer volume.

REMARKS

The claims have been amended to eliminate multiple dependency and to improve their format. None of these amendments is believed to involve any new matter. Accordingly, it is respectfully requested that the foregoing amendments be entered, that the application as so amended receive an examination on the merits, and that the claims as now presented receive an early allowance.

Respectfully submitted,



Burton A. Amernick, Reg. No. 24,852
Connolly Bove Lodge & Hutz LLP
1990 M Street, N.W., Suite 800
Washington, D.C. 20036-3425
Telephone: 202-331-7111

Date: 11-30-01

0980006-050902

MARKED-UP REVISIONS

IN THE CLAIMS:

3. (Amended) Implant layer according to Patent Claim 1 [or 2], characterized in that the channel network (6) has channel branches (10) which extend in directions which are different than the depth direction of the layer or the radial direction of the implant.

4. (Amended) Implant layer according to Patent Claim 1, [2 or 3,] characterized in that it is established on an undulating or uneven surface (3') present on the implant from the start and having a high roughness value, for example 0.4 - 5 μm , for the purpose of increasing the layer volume.

5. (Amended) Implant layer according to [any of the preceding patent claims] Patent Claim 1, characterized in that it has a thickness (T) which gives a substantial corrosion resistance for the implant as a whole.

6. (Amended) Implant layer according to [any of the preceding patent claims] Patent Claim 1, characterized in that the channel network (6) is arranged with a mouth arrangement (3', 4') towards the bone or tissue structure (5), permitting increased bone growth penetration into the channel at the said mouths (compared to conventional oxide layers).

7. (Amended) Implant layer according to [any of the preceding patent claims] Patent Claim 1, characterized in that the layer has an average thickness in the range of 0.5 - 20 μm , preferably in the range of 2 - 20 μm .

8. (Amended) Implant layer according to [any of the preceding patent claims] Patent Claim 1, characterized in that the oxide layer has a surface roughness, at its outer surface, in the range of $0.4 - 5 \mu\text{m}$.

9. (Amended) Implant layer according to [any of the preceding patent claims] Patent Claim 1, characterized in that the oxide layer has a high degree of porosity, with a number of $1 \times 10^7 - 1 \times 10^{10}$ pores/cm³.

10. (Amended) Implant layer according to [any of the preceding patent claims] Patent Claim 1, characterized in that each surface has pores or channel mouth areas with diameters or surface area sizes in the range of $0.1 - 10 \mu\text{m}$, and/or in that the total channel network or pore volume lies in a range of 5×10^{-2} and 10^{-5} cm³.

11. (Amended) Implant layer according to [any of the preceding patent claims] Patent Claim 1, characterized in that the layer consists of or comprises a titanium oxide layer.

12. (Amended) Implant layer according to [any of the preceding patent claims] Patent Claim 1, characterized in that the implant consists of a screw implant for application in the jaw bone.

13. (Amended) Implant layer according to [any of the preceding patent claims] Patent Claim 1, characterized in that the layer forms a depot for applied bone-growth-initiating or bone-growth-stimulating agent or substance (17).

14. (Amended) Implant layer according to [any of the preceding patent claims] Patent Claim 1, characterized in that the agent or the substance migrates from the depot to the bone or tissue structure (5) by means of concentration diffusion.

18. (Amended) Method according to Patent Claim 16 [or 17], characterized in that the position of the implant in the electrolyte is changed together with the composition of the electrolyte (26) and/or the voltage (28) in order to create different oxide thicknesses (T, T') and/or areas of different porosity or pore or channel characteristics.

206650.90008660

5/pols

Layer arranged on implant for bone or tissue structure, such an implant, and a method for application of the layer.

The present invention relates to a layer which can be arranged on an implant for bone or tissue structure and which is intended to constitute a boundary or barrier between the body of the implant and the structure for the purpose of increasing retention and which has, in this context, a substantial thickness. The invention also relates to an implant with such a layer, and to a method for producing the said layer on the implant.

In connection with implants, it is already well known to arrange porous surfaces and oxide layers on titanium-based material for various aims and purposes. Depending on the purpose, it has been proposed to use oxide layer thicknesses within a very wide range which extends from a few angstroms upwards. Reference may be made in purely general terms to various publications, for example the article published by Dunn et al. "Gentamicin sulfate attachment and release from anodized Ti-6Al-4V orthopedic materials" in "Journal of Biomedical Materials Research, Vol. 27, 895-900 (1993) and to the article "Formation and characterization of anodic titanium oxide films containing Ca and P" by Hitoshi Ishizawa and Makoto Ogino in "Journal of Biomedical Materials Research, Vol. 29, 65-72 (1995)". Reference may also be made in purely general terms to the patent literature, for example to US Patent Specifications 4,330,891 and 5,354,390 and to European Patent Application 95102381.1 (676179).

Considerable resources are being expended on research and development aimed at producing implants

09980005 0509022

- 2 -

which can improve the process of incorporation of the implant in bone and tissue structures, for example in the jaw bone.

5 DESCRIPTION OF THE INVENTION

The present invention is based on the recognition that the oxide layer structure used in this context can have a decisive influence for improving implantation and incorporation processes. In the prior art there is no collective grasp of the actual build-up of the oxide layer structure and the need, at least in some circumstances, to be able to use very thick oxide layers. The aim of the invention is primarily to solve this problem.

15 In connection with application of implants in bone and tissue structures, it is important to establish good corrosion resistance and, for example in connection with the use of hydrogen fluoride (HF), to avoid the occurrence of brittleness. It is also important for the oxide layer to be able to have a structure which eliminates or to a large extent counteracts mechanical stress concentrations in implants inserted in the bone or equivalent, cf. the built-in stresses which can occur in connection with etched surfaces. Further demands and requirements are that the process of incorporation of the implant in the bone or tissue can be improved. The invention solves this problem too.

20 In connection with the implant, it is possible in some cases (i.e. in one embodiment) to use bone-growth-initiating and bone-growth-stimulating agents and substances, for example those belonging to the superfamily TGF- β . It is important to be able to apply the agent or the substance to or on the implant in a technically simple and economically advantageous manner. The invention also solves this problem and proposes, through the novel oxide layer structure, a suitable depot function which can be used in long-term and optimal bone growth situations and incorporation

- 3 -

functions for the implant in the bone or equivalent.

When producing thick oxide layers (for example, thicknesses of 5 - 20 μm), it is important to be able to offer technically reliable and also economically advantageous methods. The present invention also proposes methods satisfying the conditions for production of oxide layers of the type in question. The method is based on the recognition that the electrolyte composition and/or the electrical voltages used can be of decisive importance.

SOLUTION

The feature which can principally be regarded as characterizing a layer according to the invention is that it is designed with a channel network which gives the layer a substantial porosity, and that the channel network is designed with mouths which face towards the structure and whose respective cross-sectional areas, at the surface of the layer facing towards the structure, are substantially less than the respective extents of the channels in and down into the layer as seen from the said surface.

In a preferred embodiment, the channel network comprises contiguous channel branches which extend through at least the greater part of the layer as seen from the said surface and in to the transition to the body of the implant. The layer can be established on an undulating or uneven surface present on the implant from the start and having a high roughness value (for example 0.4 - 5 μm) for the purpose of increasing the layer volume. The channel network can also have channel branches which extend in directions which are different from the depth direction of the layer (or the radial direction of the implant). The layer has a thickness which gives substantial corrosion resistance in relation to the previously proposed oxide layer arrangements. In one embodiment, the channel network can also be arranged with a mouth arrangement towards the bone or tissue structure, permitting increased

- 4 -

release of bone growth substance from the channel network via the said mouths. The layer can be given an average thickness in accordance with the attached patent claims. Preferred values in respect of the surface area sizes of the mouths of the channel network, the total channel or pore volume in the layer, the surface roughness and the porosity are likewise indicated in the attached patent claims.

An implant according to the invention can principally be regarded as being characterized by the fact that each layer present on the implant is designed with a channel network which gives the layer a substantial porosity, and by the fact that the channel network is designed with mouths which face towards the structure and whose respective cross-sectional areas, at the surface of the layer facing towards the structure, are substantially less than the respective extents of the channels in and down into the layer as seen from the said surface.

In one embodiment, the implant can consist of a screw implant for application in bone, for example dentine. In a further embodiment, the oxide layer can form a depot for applied bone-growth-initiating or bone-growth-stimulating agent or substance. The agent or the substance can migrate from the depot to the bone or tissue structure by means of concentration diffusion, which can be optimized by means of the channel network's mouth arrangement facing towards the bone or tissue structure. In a preferred embodiment, the layer consists of or comprises a titanium oxide layer.

A method according to the invention starts out from anodic oxidation of the implant material in question. The method can principally be characterized by the fact that diluted inorganic acids, diluted organic acids and/or small quantities of hydrofluoric acid or hydrogen peroxide are added to the electrolytic composition which is used in the method, and by the fact that the energy source is chosen to operate with a

- 5 -

voltage value of at least 150 volts. Thus, for example, voltage values in the range of 200 - 400 volts can be used.

In a preferred embodiment, the voltage varies at times for the same implant in order to create different channel or pore sizes within the same surface area or surface areas of the implant. In a further embodiment, different porosities or pore or channel characteristics can be obtained by means of the position of the implant in the electrolyte being changed, together with the choice of the electrolyte composition and/or the voltage used. The oxide thickness can also be varied by means of the said parameters.

ADVANTAGES

By means of what has been proposed above, an improved implantation process is obtained, and, using the proposed oxide layer thicknesses at the upper end of the proposed range, the invention goes against the ideas which have hitherto been accepted in the technical field, thus opening up new avenues within the art. The concentration diffusion in conjunction with the use of bone-growth-initiating and bone-growth-stimulating substances can be considerably facilitated by the proposed channel make-up of the structure. The implant can be made commercially available with a finished oxide layer having the stated properties, and the novel method meets the conditions for economically advantageous layer production and implant production.

DESCRIPTION OF THE FIGURES

A presently proposed embodiment of a layer, an implant and a method according to the invention will be described below with reference to the attached drawings, in which:

Figure 1 shows, in longitudinal section, an illustrative embodiment of a titanium oxide layer

- 6 -

produced on an implant body, the oxide layer starting from a relatively plane surface on the implant body,

Figure 2 shows, in longitudinal section, an example of the position of the oxide layer on an undulating surface or on a surface with a high degree of surface roughness,

Figure 3 shows a plan view, from outside, of an example of a mouth arrangement for a channel network arranged in the oxide layer,

Figure 4 shows, in vertical section and in diagrammatic form, a channel network for an oxide layer produced on an implant body, where the implant with associated oxide layer is applied in a partially shown bone and/or tissue structure in the human body, and in the oxide layer there is a channel network with a mouth arrangement facing towards the structure,

Figure 5 shows a side view of equipment for anodic oxidation of an implant,

Figure 6 shows, in diagram form, the voltage and current functions used in association with the oxidation process, and

Figure 7 shows, in table form, parameters for building up different titanium oxide layers.

DETAILED EMBODIMENT

In Figure 1, reference number 1 indicates parts of an implant body. As will be described below, the implant body has been treated in an oxidation function, resulting in an oxidation layer 2 having been formed on its outer surface. The oxidation layer can be built up on a surface structure which is relatively smooth from the outset, as has been indicated by 3 in Figure 1. The oxide layer 2 has a considerable thickness T. The layer can assume values of between 0.5 and 10 μm , with the values preferably being towards the upper limit of the range. According to the invention, the invention will function primarily in the range of 2 - 10 μm , although values as low as 0.5 μm may be used in certain exceptional cases. The outer surface 2a of the oxide

- 7 -

layer must have a surface roughness within the range of 0.4 - 5 μm . According to what is described below, the oxide layer 2 has a high degree of porosity and encloses a channel network of specific type.

5 Figure 2 shows an example which differs from that in Figure 1 and where the oxide layer 2' has been built up on a surface structure 3' located on the implant 1' and having a relatively high degree of surface roughness, which has been obtained in a manner
10 known per se upon production of the implant (e.g. by etching). The embodiment according to Figure 2 satisfies conditions for a relatively greater oxide layer volume than in the case according to Figure 1.

Figure 3 shows, from the outside of the oxide
15 layer 2'', mouths 3, 4 leading from the channel network mentioned above.

In Figures 1, 2 and 3, the scale is shown at the bottom right-hand corner, i.e. the size 10 μm length in each figure.

20 In Figure 4, the implant is indicated by 1'' and the oxide layer produced on the implant is indicated by 2'''. In Figure 4, a bone or tissue structure is indicated symbolically by 5. The structure can consist, for example, of a jaw bone in which the
25 implant can be screwed down into the bone or equivalent. The implant can thus consist of or comprise titanium material, which means that the layer 2''' consists of a titanium oxide layer. The screw or the thread of the implant is not indicated in Figure 4, but
30 reference may be made to the already disclosed prior art and to known implants. The corresponding thread in the jaw bone 5 is not shown either, but here again reference may be made to the prior art. The oxide layer
35 2''' which is designed with the considerable thickness T', e.g. a thickness in the range of 5 - 25 μm , is provided with a channel network which is indicated symbolically by the arrow 6. In accordance with the above, the channel network has mouths or openings 3', 4'. The channel network branches down and/or in to the

- 8 -

oxide layer, as seen from the outside 7 of the oxide layer. The channel network comprises different channel parts, for example 8, 9, 10. Channel routes can be established through the channel network which are made up of different channel parts and run from the outside 2a' of the layer 2''' and down or in towards a transition 11 between the implant and the oxide layer. Such a continuous channel formation is established with the channel parts or channel branches 12, 13, 14, 15 in the figure. A characteristic of the channel or pore formation according to the invention is that the surface area or the diameter D of each mouth is substantially less than the respective channel boundary or pore depth, for example a pore depth H. According to the above, the pore depth or channel depth can be significant and correspond, for example, to the said thickness T'. The channels can extend in the direction of depth of the oxide layer 2''' and/or in directions which are different than this direction, or in the radial direction R of the implant. The channel branches or the channel parts can be straight and/or curved, a curved channel branch having been indicated by 16 in Figure 4.

It will be appreciated that such a channel system can constitute a depot for substance which stimulates and/or initiates bone growth, and this has been symbolized by 17 in Figure 4. A substance thus introduced into the channel network can, by means of concentration diffusion, migrate out into the bone or tissue structure, as has been symbolized by the arrow 18 in Figure 4. Correspondingly, bone or tissue organisms can pass into the system in conjunction with the said diffusion. It will be appreciated that the mouths can be given different sizes and can create conditions for bone growth with a specific penetration function in the mouth arrangement, contributing to the degree of incorporation of the implant in the structure. The oxide layer of high porosity can be formed with $1 \times 10^7 - 1 \times 10^{10}$ pores (channel

- 9 -

mouths)/cm². The diameter sizes can be chosen in the range of 0.1 - 10 μ m, and one and the same surface area of the oxide layer can have pores or channel mouths of different diameters or surface areas. A total volume
5 for the channel network according to Figure 4 can be chosen in a range of 5×10^{-2} and 10^{-5} cm³.

The titanium oxide layers according to the above are preferably produced by so-called anodic oxidation, which is an electrochemical process. The
10 principle and the procedure for producing the layers in question are described with reference to Figures 5 and 6. In Figure 5, a container is indicated by 20. A titanium anode is indicated by 21, and a porous meshed cathode is indicated by 22. A Teflon insulation of the
15 titanium anode is indicated by 23, and the anodes extend through a Teflon cover 24. A magnetic agitator 25 is also included. The attachments for anode and cathode are indicated by 21' and 22', respectively. The implant or the parts of the implant which are to be
20 prepared are preferably mechanically worked by turning, milling, polishing, etc. The implant or parts in question comprise titanium surfaces which are to be treated in the electrochemical process. The implant or parts in question are mounted on a holder which is
25 immersed in a bath in the container consisting of an electrolyte 26. Those parts of the implant which are not to be treated are masked by a liquid-tight protective sleeve or alternatively with a suitable lacquer which is arranged on the parts which are not to
30 be treated. The implant or its said parts are in electrical contact, via the holder, with the attachment 21' above the surface of the electrolyte. In the electrolyte, the said cathode 22 functions as a counter-electrode. This counter-electrode is made of
35 suitable material, for example Pt, gold or graphite. The counter-electrode is preferably mounted on the holder in such a way that the whole arrangement is jointly fixed in the electrolyte bath 26. The anodic oxidation is obtained by applying an electrical voltage

05060005.0506002

- 10 -

between implant/implant part/implant parts and counter-electrode, whereupon the implant or its part or parts in question are given positive potential. The implant, implant part/implant parts, the counter electrode and the electrolyte constitute an electrochemical cell in which the implant or its respective part forms an anode. The difference in electrical potential between implant/implant part and counter-electrode gives rise to a stream of negatively (positive) charged electrolyte ions to the implant or implant part (counter-electrode). If the electrolyte has been chosen suitably, the electrolyte reactions in the cell result in formation of an oxide layer on the implant or surface of the implant part. Since the electrode reactions also result in gas formation, the electrolyte should be stirred in a suitable manner, which is done with magnetic agitator 25, preventing gas bubbles from remaining on the electrode surfaces.

The formation of the titanium oxide layer and its final properties are affected by a number of parameters in the process, e.g. the electrolyte's composition and temperature, the voltage and current applied, the electrode geometry and the treatment time. The way in which the desired layers are produced is described in more detail below. Examples are also given of how the process parameters affect various properties of the oxide layers and how the oxide thickness and porosity can be varied.

To achieve the desired layer properties, one starts, for example, from a mechanically worked surface which can be turned or polished. Cast and pressed implants or implant parts can also be used. The surface is cleaned in a suitable manner, for example by ultrasound cleaning in organic solvents in order to remove impurities from previous production stages. The cleaned implant or the cleaned implant part is secured in the said container, which is secured together with the counter-electrode on the holder. The arrangement can then be immersed in the electrolyte. The two

09980006.050902

- 11 -

electrodes are thereafter coupled to a voltage source (not shown) and an electrical voltage is applied, whereupon the process commences. The process is terminated, after the desired time, by interrupting the voltage application.

The electrical voltage can be applied in different ways, cf. also Figure 6. In a galvanostatic process, the current is kept constant, the voltage being allowed to vary according to the resistance in the cell, whereas, in a potentiostatic process, the voltage instead is kept constant and the current is allowed to vary. The desired layers are formed preferably by using a combination of galvanostatic and potentiostatic control. Galvanostatic control is used in a first stage, the voltage being allowed to increase to a preset value. When this voltage value has been reached, the process changes over to potentiostatic control. On account of the resistance of the oxide layer which has been formed, the current drops in this state.

Figure 6 shows the development of the current and voltage over time. The exact appearance of the curves depends on various process parameters and also reflects the formation of the oxide layer and its properties.

Up to a certain voltage, which is dependent on electrolyte, relatively thin oxide layers ($< 0.2 \mu\text{m}$) are obtained, where the oxide layer thickness is approximately linearly dependent on the applied voltage, and independent of treatment time after the maximum voltage has been reached. These layers are essentially closed, and only in exceptional circumstances do they have a partially open porosity. For most electrolytes, the critical voltage is about 100 volts.

To achieve the desired porous oxide layers, it is necessary to apply considerably higher voltages in excess of 150 volts, typically 200 - 400 volts, depending on electrolyte. At these voltages, the oxide

096006-050902

- 12 -

thickness is no longer linearly dependent on the voltage, and, instead, considerably thicker layers can be produced. For certain electrolytes, the oxide thickness at these voltages is also dependent on the treatment time after the maximum voltage has been reached. Suitable electrolytes for achieving porous layers using this method are diluted inorganic acids (e.g. sulphuric acid, phosphoric acid, chromic acid) and/or diluted organic acids (e.g. acetic acid, citric acid), or mixtures of these.

The implant which is treated in sulphuric acid has a surface with high density and open pores. Some 20% of the surface consists of pores or channels/channel branches, with sizes (diameters) preferably in the range of 0.1 - 0.5 μm . The thickness of the layer can be 2 μm . The implant which is treated in phosphoric acid has a similar density of pores. The pore size distribution can differ considerably. In the case shown, pore sizes can be chosen preferably in the range of 0.3 - 0.5 μm , but a good number of larger pores (up to 1.5 μm) can also be present on the surface. The oxide thickness in this embodiment is 5 μm .

The table according to Figure 7 shows the structure of the oxide layer made with different process parameters in this method. The parameters shown are the electrolyte composition, voltage (volts), current (mA), time, pore diameter, pore density, porosity and oxide thickness.

The invention is not limited to the embodiment described above by way of example, but can be modified within the scope of the attached patent claims and the inventive concept.

- 13 -

PATENT CLAIMS

1. Layer (2) which can be arranged on an implant
5 (1) for bone or tissue structure (5) and which constitutes a boundary or barrier between the body of the implant and the structure for the purpose of increasing retention and which has, in this context, a substantial thickness (T), characterized in that the
10 layer (2) is designed with a channel network (6) which gives the layer a substantial porosity, and in that the channel network (6) is designed with mouths (3, 4) which face towards the structure and whose respective cross-sectional diameters (D), at the surface (2a) of
15 the layer facing towards the structure (5), are substantially less than the respective extents (H) of the channels in and down into the layer as seen from the said surface (2a').
2. Implant layer according to Patent Claim 1,
20 characterized in that the channel network (6) comprises contiguous channel branches (12, 13, 14, 15) which extend through at least the greater part of the layer (2''') from the said surface (2a') and to the transition (11) from the layer to the body (1'') of the
25 implant.
3. Implant layer according to Patent Claim 1 or 2, characterized in that the channel network (6) has channel branches (10) which extend in directions which are different than the depth direction of the layer or
30 the radial direction of the implant.
4. Implant layer according to Patent Claim 1, 2 or 3, characterized in that it is established on an undulating or uneven surface (3') present on the implant from the start and having a high roughness
35 value, for example 0.4 - 5 μm , for the purpose of increasing the layer volume.
5. Implant layer according to any of the preceding patent claims, characterized in that it has a thickness (T) which gives a substantial corrosion resistance for

- 14 -

the implant as a whole.

6. Implant layer according to any of the preceding patent claims, characterized in that the channel network (6) is arranged with a mouth arrangement (3', 4') towards the bone or tissue structure (5), permitting increased bone growth penetration into the channel at the said mouths (compared to conventional oxide layers).

7. Implant layer according to any of the preceding
10 patent claims, characterized in that the layer has an
average thickness in the range of 0.5 - 20 μm ,
preferably in the range of 2 - 20 μm .

8. Implant layer according to any of the preceding patent claims, characterized in that the oxide layer
15 has a surface roughness, at its outer surface, in the range of 0.4 - 5 μm .

9. Implant layer according to any of the preceding patent claims, characterized in that the oxide layer has a high degree of porosity, with a number of 1×10^7 - 1×10^{10} pores/cm³.

10. Implant layer according to any of the preceding patent claims, characterized in that each surface has pores or channel mouth areas with diameters or surface area sizes in the range of 0.1 - 10 μm , and/or in that
25 the total channel network or pore volume lies in a range of 5×10^{-2} and 10^{-5} cm^3 .

11. Implant layer according to any of the preceding patent claims, characterized in that the layer consists of or comprises a titanium oxide layer.

30 12. Implant layer according to any of the preceding
patent claims, characterized in that the implant
consists of a screw implant for application in the jaw
bone.

13. Implant layer according to any of the preceding
35 patent claims, characterized in that the layer forms a
depot for applied bone-growth-initiating or bone-
growth-stimulating agent or substance (17).

14. Implant layer according to any of the preceding patent claims, characterized in that the agent or the

- 15 -

substance migrates from the depot to the bone or tissue structure (5) by means of concentration diffusion.

15. Implant (1) for bone or tissue structure (5) and comprising one or more layers (2) which constitute
5 a boundary (or boundaries) between the body (1) of the implant and the structure (5) for the purpose of increasing retention and which each have, in this context, a substantial thickness, characterized in that each layer is designed with a channel network (6) which
10 gives the layer (2) a substantial porosity, and in that the channel network (6) is designed with mouths (3, 4) which face towards the structure and whose respective cross-sectional diameters (D), at the surface of the layer facing towards the structure, are substantially
15 less than the respective extents (H) of the channels in and down into the layer as seen from the said surface (2a').

16. Method for producing, by anodic oxidation, on an implant comprising or consisting of titanium,
20 relatively thick oxide layers (2) on one or more titanium surfaces which are intended to be placed against or arranged next to one or more tissue and/or bone growth areas (5), where at least the part or parts supporting the said surface or surfaces are
25 prepared and immersed in electrolyte (26) and the implant is brought into contact with an electrical energy source above the electrolyte surface and the oxidation process is established by also connecting to the energy source a counter-electrode arranged in the
30 electrolyte (26), characterized in that diluted inorganic acids, diluted organic acids and/or small quantities of hydrofluoric acids or hydrogen peroxide are added to the electrolytic composition, and in that the energy source is chosen to operate with voltage
35 values of at least 150 volts, for example with voltage values in the range of 200 - 400 volts.

17. Method according to Patent Claim 12, characterized in that the voltage (28) is varied at times for the same implant in order to create different

0980008-050902

- 16 -

channel or pore sizes within the same surface area.

18. Method according to Patent Claim 16 or 17, characterized in that the position of the implant in the electrolyte is changed together with the
5 composition of the electrolyte (26) and/or the voltage (28) in order to create different oxide thicknesses (T, T') and/or areas of different porosity or pore or channel characteristics.

09980006 050902

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/72776 A1


- (51) International Patent Classification: A61C 8/00, (74) Agent: OLSSON, Gunnar; Nobel Biocare AB (publ), A61L 27/04, 27/54, Box 5190, S-402 26 Göteborg (SE).
- (21) International Application Number: PCT/SE00/01026 (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 23 May 2000 (23.05.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 9901974-7 31 May 1999 (31.05.1999) SE
- (71) Applicant (for all designated States except US): NOBEL BIO CARE AB (publ) [SE/SE]; Box 5190, S-402 26 Göteborg (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HALL, Jan [SE/SE]; Stabbegetan 2A, S-416 80 Göteborg (SE). LAUSMAA, Jukka [SE/SE]; Trojenborgsplatzen 3, S-415 03 Göteborg (SE).
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: LAYER ARRANGED ON IMPLANT FOR BONE OR TISSUE STRUCTURE, SUCH AN IMPLANT, AND A METHOD FOR APPLICATION OF THE LAYER



(57) Abstract: A layer (2''') is arranged on an implant (1'') for bone or tissue structure (5). The layer constitutes a boundary or barrier between the actual or unoxidized body (1'') of the implant and the structure for the purpose of increasing retention and has, in this context, a substantial thickness (T'). The layer is designed with a channel network (6) which gives the layer a substantial porosity. The channel network is designed with mouths (3', 4') which face towards the structure and whose respective cross-sectional diameters (D), at the surface (2a') of the layer facing towards the structure (5), are substantially less than the respective extents (e.g. H) of the channels in and down into the layer as seen from the said surface (2a').

WO 00/72776 A1

Fig. 1






Fig. 2



2 / 5

Fig. 3

N42, 0.15M H_2SO_4 + 0.25M H_3PO_4 , 300 V, 200 mA, 300 s



4/5

Fig. 5





Fig. 6



FAG-7

Electrolyte	U (V)	I (mA)	Time (s)	Pore diam. (μm)	Pore density ($10^9/\text{cm}^2$)	Porosity (%)	Oxide thickness (μm)
0.35M H_2SO_4	250	300	400	n.a.			9.2-13.5
0.35M H_2SO_4	250	800	300	n.a.			19.1-21.3
1.0M H_2SO_4	200	200	400	n.a.			5.8-6.5
0.35M H_2SO_4	200	200		0.28-	0.45	5.65	3.5-7.0
+160 min.				0.92			
0.35M H_2SO_4	200	200	300	0.06-	2.48	6.47	2.2-2.8
etched				0.43			
0.15M H_2SO_4	300	200	300	0.31-	0.078	4.16	2.9-6.5
				2.27			
0.25M H_2SO_4	300	200	300	0.31-	0.080	7.84	3.6-6.5
				2.65			
0.35M H_2SO_4	300	1400	300	0.31-	0.060	10.69	3.6-11.0
				4.06			

DECLARATION FOR PATENT APPLICATION

21547/0283

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **LAYER ARRANGED ON IMPLANT FOR BONE OR TISSUE STRUCTURE, SUCH AN IMPLANT, AND A METHOD FOR APPLICATION OF THE LAYER**
 the specification of which: (check one)

[] I am attached hereto.

[XX] was filed on May 23, 2000, as United States Patent Application Serial No. or PCT International Application Number PCT/SE00/01026, and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 CFR § 1.56(a).

Prior Foreign Application(s): I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate listed below, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

92 01974-7 ✓ (Application No.)	Sweden ✓ (Country)	11/May/1992 ✓ (Day/Month/Year Filed)	[XX] YES	Priority Claimed [] NO
(Application No.)	(Country)	(Day/Month/Year Filed)	[] YES	[] NO
(Application No.)	(Country)	(Day/Month/Year Filed)	[] YES	[] NO
(Application No.)	(Country)	(Day/Month/Year Filed)	[] YES	[] NO

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below or 34 U.S.C. § 365(c) of any PCT International Application designating the United States of America listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT application in the manner provided by 35 U.S.C. § 112, first paragraph, I acknowledge the duty to disclose material information as defined in 37 CFR § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(U.S. or PCT Application Serial No.) (U.S. or PCT Filing Date) (Status - patented, pending, abandoned)

(U.S. or PCT Application Serial No.) (U.S. or PCT Filing Date) (Status - patented, pending, abandoned)

I hereby appoint the following registered practitioners: Rudolf E. Hutz, Reg. No. 22,397; Harold Pezner, Reg. No. 22,112; Richard M. Beck, Reg. No. 22,580; Paul E. Crawford, Reg. No. 24,397; Burton A. Amernick, Reg. No. 24,352; Stanley B. Green, Reg. No. 24,351; Morris Liss, Reg. No. 24,510; George R. Petli, Reg. No. 27,360; Patricia J. Srinik Rajgowski, Reg. No. 33,791; Robert G. McMorris, Jr., Reg. No. 30,962; Ashley I. Pezner, Reg. No. 35,646; William E. McShane, Reg. No. 32,707; Mary W. Bourke, Reg. No. 30,982; Gerard M. O'Rourke, Reg. No. 39,794; James M. Olsen, Reg. No. 40,408; Francis DiGiovanni, Reg. No. 37,310; Eric J. Eveln, Reg. No. 42,517; Daniel C. Mulvey, Reg. No. 44,899; Patrick J. Wells, Reg. No. 46,455; Thomas F. Poche, Reg. No. 45,017; Patrick H. Higgins, Reg. No. 38,708; Christine M. Hansen, Reg. No. 40,634; Daniel Harrison, Reg. No. 47,611; Gary Bridge, Reg. No. 44,560; Larry J. Hume, Reg. No. 44,163; Joseph Barrera 44,532; John A. Evans, (Agent) 44,100; and Elliot C. Mendelson (Agent), Reg. No. 42,528, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Send Correspondence and Direct Telephone Calls to:

Burton A. Amernick
(202) 331-7111

Burton A. Amernick
Connolly Bove Lodge & Hutz LLP
P.O. Box 19088
Washington, D.C. 20036-0088 U.S.A.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 Full name of sole or first inventor Jan Hall

Inventor's Signature

Residence Address

Citizenship

Post Office Address

Stabergatan 2A, S-416 80 Göteborg, Sweden
Swedish
Same as above

Date April 19, 2002

[XX] See next page for additional inventors

DECLARATION FOR PATENT APPLICATION**Page 2**

2-67P Full name of second joint inventor (if any)

JUKKA LAUSMAA

Inventor's Signature

Residence Address

Citizenship

Post Office Address

Trojenborgsplatsen 3, S-415 03, Goteborg, SWEDEN Date April 19, 2002
Swedish
Same as above

Full name of third joint inventor (if any)

Inventor's Signature

Residence Address

Citizenship

Post Office Address

Date

Full name of fourth joint inventor (if any)

Inventor's Signature

Residence Address

Citizenship

Post Office Address

Date

Full name of fifth joint inventor (if any)

Inventor's Signature

Residence Address

Citizenship

Post Office Address

Date

Full name of sixth joint inventor (if any)

Inventor's Signature

Residence Address

Citizenship

Post Office Address

Date

Full name of seventh joint inventor (if any)

Inventor's Signature

Residence Address

Citizenship

Post Office Address

Date

Full name of eighth joint inventor (if any)

Inventor's Signature


Residence Address

Citizenship

Post Office Address

Date

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

✓ Scanned copy is best available. Some drawings are too dark.

09980005 050902